ALI BEHBAHANI

Ali Behbahani serves as a General Partner at New Enterprise Associates (NEA), one of the world's largest and most active venture capital firms. Based in NEA's Menlo Park office, Behbahani is a key figure in the firm's robust healthcare investment practice, bringing a deep understanding of both scientific innovation and market dynamics to his role. His expertise lies in identifying and nurturing groundbreaking companies that are poised to transform patient care and improve health outcomes globally.

Behbahani's investment focus at NEA is primarily within the healthcare sector, encompassing a broad range of areas including biopharmaceuticals, medical devices, and healthcare services. He is particularly drawn to companies that leverage cutting-edge science and technology to address unmet medical needs. His portfolio reflects a strategic emphasis on novel therapeutics, diagnostics, and innovative care delivery models that have the potential for significant clinical and commercial impact. He actively partners with entrepreneurs who are developing solutions for complex diseases and improving the efficiency and accessibility of healthcare.

Before joining NEA in 2007, Behbahani honed his financial and healthcare industry acumen at Morgan Stanley, where he worked in the Global Healthcare Group. This experience provided him with a strong foundation in evaluating healthcare businesses and understanding market trends. Academically, Behbahani possesses an impressive background that underpins his investment philosophy. He earned his M.D. from the University of Pennsylvania School of Medicine and an MBA from the Wharton School of the University of Pennsylvania. Prior to his graduate studies, he completed his B.S. in Biology at Duke University. This unique blend of medical and business education allows him to assess investment opportunities from both a scientific validity and commercial viability perspective.

Throughout his tenure at NEA, Ali Behbahani has been instrumental in the success of numerous portfolio companies. While specific investment details are often proprietary, his involvement has spanned companies like CRISPR Therapeutics, a leader in gene-editing technology; Loxo Oncology, which developed targeted cancer therapies; and Rhythm Pharmaceuticals, focused on rare genetic disorders affecting appetite and weight. His strategic guidance and extensive network have been invaluable to these and many other ventures, helping them navigate complex development pathways and achieve significant milestones. Behbahani's commitment to advancing healthcare innovation makes him a pivotal investor in the life sciences landscape.